Zoetis: The Growth Story Has Broken, But The Valuation Finally Makes Sense (NYSE:ZTS)
· seekingalpha.com
Zoetis (ZTS) trades at 12x forward earnings with a ~3% yield after a big drawdown—see why its margins, buybacks, and value setup make it a Buy. Read the full analysis here.
Zoetis ( ZTS ) is the dominant global leader in animal health, developing and commercializing medicines, vaccines, diagnostics, biodevices, genetic tests, and p...